Land­mark Amy­lyx OK spurs de­bate; Some... pos­i­tive? Alzheimer's da­ta; Can­cer tri­al bot­tle­neck; Sanofi's CRISPR bet; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Af­ter brief stops in Paris and Boston, John Car­roll and the End­points crew are stay­ing on the road in Oc­to­ber with their re­turn for a live/stream­ing EU­BIO22 in Lon­don. The hy­brid event fire­side chats and pan­els on mR­NA, on­col­o­gy and the crazy pub­lic mar­ket. We hope you can join him there.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.